Rheumatic diseases and syndromes induced by cancer immunotherapy : a handbook for diagnosis and management / Maria E. Suarez-Almazor, Leonard H. Calabrese, editors.
2021
RC927 .R44 2021
Linked e-resources
Linked Resource
Online Access
Concurrent users
Unlimited
Authorized users
Authorized users
Document Delivery Supplied
Can lend chapters, not whole ebooks
Details
Title
Rheumatic diseases and syndromes induced by cancer immunotherapy : a handbook for diagnosis and management / Maria E. Suarez-Almazor, Leonard H. Calabrese, editors.
ISBN
3030568245 (electronic book)
9783030568245 (electronic bk.)
3030568237
9783030568238
9783030568245 (electronic bk.)
3030568237
9783030568238
Published
Cham, Switzerland : Springer, [2021]
Language
English
Description
1 online resource (xiv, 363 pages) : illustrations (some color)
Item Number
10.1007/978-3-030-56824-5 doi
Call Number
RC927 .R44 2021
Dewey Decimal Classification
616.723
Summary
With the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk-benefit ratios when managing patients with rheumatic irAE. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.
Bibliography, etc. Note
Includes bibliographical references and index.
Access Note
Access limited to authorized users.
Digital File Characteristics
text file
PDF
Source of Description
Online resource; title from PDF title page (SpringerLink, viewed April 1, 2021).
Available in Other Form
Print version: 9783030568238
Print version: 9783030568252
Print version: 9783030568252
Linked Resources
Online Access
Record Appears in
Online Resources > Ebooks
All Resources
All Resources
Table of Contents
Part I. Introduction. Cancer Immunology and the evolution of immunotherapy ; Cancer immunotherapy: overview of immune checkpoint inhibitors ; Immunopathogenesis of immune-related adverse events from cancer immunotherapy
Part II. Immune-related adverse events with immune-checkpoint inhibitors. Arthritis ; Polymyalgia rheumatica ; Myositis ; Sicca syndromes ; Sarcoidosis ; Miscellaneous rheumatic syndromes ; Non-rheumatic immune-related adverse events ; Immune-related adverse events with other cancer immunotherapies
Part III. Cancer immunotherapy in patients with pre-existing rheumatic diseases. Inflammatory arthritis ; Other rheumatic autoimmune diseases
Part IV. General principles of management. Management of rheumatic immune-related adverse events (irAEs): general principles ; Benefit-risk considerations ; Patient education and shared-decision making.
Part II. Immune-related adverse events with immune-checkpoint inhibitors. Arthritis ; Polymyalgia rheumatica ; Myositis ; Sicca syndromes ; Sarcoidosis ; Miscellaneous rheumatic syndromes ; Non-rheumatic immune-related adverse events ; Immune-related adverse events with other cancer immunotherapies
Part III. Cancer immunotherapy in patients with pre-existing rheumatic diseases. Inflammatory arthritis ; Other rheumatic autoimmune diseases
Part IV. General principles of management. Management of rheumatic immune-related adverse events (irAEs): general principles ; Benefit-risk considerations ; Patient education and shared-decision making.